VANCOUVER, British Columbia, Dec. 21, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce the launch of its new website and provide an operational update.
Launch of New Marketing Materials
Abattis has recently unveiled its new marketing and branding materials, developed in conjunction with media company Canada One Communications Inc. (“Canada One”). Marketing materials include an updated website, corporate presentation and conference materials all highlighting Abattis’ new brand imagery (“new marketing materials”).
The new marketing materials now reflect the Company’s focus on its primary business lines which are: 1) Cultivation 2) Products and 3) Services. Under the Cultivation division, the new marketing materials feature up to date information on Gabriola Green Farms (“Gabriola”) and the recent acquisition of Select Strains Genetics (“Select Strains”). Under the Products division, the new marketing materials reflect the Company branded Vaporizers, which can be purchased directly from the Company’s website as well as the Company’s recently launched COMFORTTM therapeutic, which can also be purchased on the website through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence”). Under the Services division, the new marketing materials reflect the Company’s many service offerings such as regulatory advisory, formulation, research and development. The Company’s new corporate presentation can be downloaded directly from the Company’s website.
“We are really excited to share the new direction that Abattis is going in 2019, and as such there was a need for a refresh that would convey a streamlined, vertically-integrated cannabis company,” stated Rob Abenante, President and CEO of Abattis.
O’Cannabiz Conference and Expo
Abattis is also pleased to share highlights from its presence at the recent O’Cannabiz Expo and Conference (“O’Cannabiz”). Abattis investors and other industry professionals met with the Abattis Team from December 10-11th at the Parq Casino in Vancouver, BC, which had over 200 industry and media speakers. The conference was filled with cannabis industry businesses and interested parties and Abattis was able to display COMFORTTM, the cannabinoid infused nutraceutical developed and distributed through Vergence. The Company also had on display its full line of vaporizers, which were available for investors to demo and purchase. The focus of the event for the Company was to meet with investors and shareholders and answer questions, show case the Company’s new product lines and demonstrate their vision for the future of Company, which focuses on revenue generating business lines.
“The reception of our team and the new visual direction was an outstanding success at O’Cannabiz and going forward we will continue to keep the public updated on the development of the Abattis brand,” stated Patrick Mitchell, COO of Abattis.
Acquisition Update
On November 22, 2018, Abattis acquired (the “Acquisition”) all of the issued and outstanding common shares of Select Strains in exchange for the issuance to Select Strains’ former shareholder of 41,666,667 Abattis common shares at a deemed price of $0.12 per share, for an aggregate deemed issue price of $5 million. Select Strains has a portfolio of over 140 laboratory-tested craft cannabis strains, which Abattis hopes to leverage through licensing arrangements, clone fulfillment, tissue culture and strain patenting services and eventually through its late-stage ACMPR licensed producer applicant, Gabriola. Due to an oversight, the Company did not timely disseminate a news release or file a Form 9 – Notice of Issuance of Securities with the Canadian Securities Exchange respecting the closing. The Company confirms that it has now filed the required Form 9 and apologizes to its shareholders for the delay in informing them of the closing.
“We are excited to have completed the Acquisition and apologize for our delay in updating our shareholders and the investment community at large. We remain committed to transparent and timely disclosure and have taken measures internally to ensure that future communications go out on time and in compliance with securities laws,” stated Abattis President and CEO, Rob Abenante.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company.
The Company’s flagship cultivation asset is located on beautiful British Columbia’s Gabriola Island. Starting with 26,000 square feet and expandable across 8 acres, Gabriola plans to grow medical-grade marijuana as well as select craft strains of infamous “BC Bud”. In addition to concurrently developing the greenhouses and moving through the final stages of the licence process, Abattis has been aggressively building its portfolio of complimentary assets which includes the acquisition of 140 genetic strains and the acquisition of a robust portfolio of fertilizers and nutrients, custom formulated for the emerging cannabis market.
Abattis has also continued to organically grow its products and services divisions as it strives to become one of the industry’s most dynamic vertically integrated cannabis companies. This ranges from its Abattis-branded vaporizer line, now sold nationally in Shefield and Sons, to the recent launch of its first proprietary cannabinoid therapeutic, Comfort, formulated to treat chronic pain and inflammation. Abattis also continues to service the cultivation industry through its preferred service agreements with Northern Vine, a licensed laboratory which it recently sold to Emerald Health Therapeutics, and Dicentra, which is one of Canada’s largest regulatory advisory firms.
Uniquely positioned in all areas from seed to sale, Abattis forges forward across all its divisions as it aims to become a premiere cannabis company. Through aggressive acquisitions and focused organic growth, Abattis looks ahead to the next chapter of its growth as it focuses on revenue generation for 2019.The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
“Rob Abenante”
Robert Abenante, President & CEO
For more information, please visit the Company’s website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at investors@abattis.com. Abattis IR is managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: prospects of the global cannabis markets; the expected benefits from the Company’s recent sales and marketing activities; the Company’s hope to leverage Select Strains’ portfolio through licensing arrangements, clone fulfillment, tissue culture and strain patenting services and eventually through Gabriola; and the Company commitment to ensuring that future communications go out on time and in full compliance with securities laws. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.